457 related articles for article (PubMed ID: 29492779)
1. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.
Fowler AJ; Moussa CE
CNS Drugs; 2018 Jan; 32(1):1-11. PubMed ID: 29492779
[TBL] [Abstract][Full Text] [Related]
2. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.
Rott R; Szargel R; Shani V; Bisharat S; Engelender S
CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368
[TBL] [Abstract][Full Text] [Related]
3. alpha-Synuclein: a therapeutic target for Parkinson's disease?
Maguire-Zeiss KA
Pharmacol Res; 2008; 58(5-6):271-80. PubMed ID: 18840530
[TBL] [Abstract][Full Text] [Related]
4. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
Török N; Majláth Z; Szalárdy L; Vécsei L
Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
[TBL] [Abstract][Full Text] [Related]
5. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M; Brekk OR; Stefanis L
Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
[TBL] [Abstract][Full Text] [Related]
6. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
8. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
Wrasidlo W; Tsigelny IF; Price DL; Dutta G; Rockenstein E; Schwarz TC; Ledolter K; Bonhaus D; Paulino A; Eleuteri S; Skjevik ÅA; Kouznetsova VL; Spencer B; Desplats P; Gonzalez-Ruelas T; Trejo-Morales M; Overk CR; Winter S; Zhu C; Chesselet MF; Meier D; Moessler H; Konrat R; Masliah E
Brain; 2016 Dec; 139(Pt 12):3217-3236. PubMed ID: 27679481
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
Lingor P; Carboni E; Koch JC
J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches to target alpha-synuclein pathology.
Brundin P; Dave KD; Kordower JH
Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
Amer DA; Irvine GB; El-Agnaf OM
Exp Brain Res; 2006 Aug; 173(2):223-33. PubMed ID: 16733698
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease.
Engelender S
Autophagy; 2008 Apr; 4(3):372-4. PubMed ID: 18216494
[TBL] [Abstract][Full Text] [Related]
14. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
15. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
[TBL] [Abstract][Full Text] [Related]
16. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
17. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG
Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
Pozo Devoto VM; Falzone TL
Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
20. Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets?
Jiang TF; Chen SD
Neurosci Bull; 2012 Oct; 28(5):649-57. PubMed ID: 22961477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
